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ParkinMacroautophagy (hereafter termed autophagy) is a cellular membrane-trafficking process that functions
to deliver cytoplasmic constituents to lysosomes for degradation. Autophagy operates at basal levels to
turn over damaged and misfolded proteins and it is the only process for the turnover of organelles.
The process is therefore critically important for the preservation of cellular integrity and viability.
Autophagy is also highly adaptable and the rate and cargoes of autophagy can be altered to bring about
desired cellular responses to intracellular and environmental cues, disease states and a spectrum of
pharmaceutical drugs. As a result, there is much interest in understanding the dynamics of autophagy
in a variety of situations. To date, the majority of assays to monitor autophagy either measure changes
in a parameter of the process at a set point in time or use markers/tracers to monitor flow of
membrane-bound proteins from one point in the process to another. As such, these assays do not
measure changes in endogenous cargo degradation which is the ultimate end-point of the autophagy pro-
cess. We describe here an assay to measure autophagic cargo degradation by engineering cells to degrade
mitochondria en masse. We show that this ‘enhanced-mitophagy’ assay can be used to measure
differences in the rate of autophagy between different cells or in response to agents which are known
to promote or inhibit autophagic flux. We consider therefore that this assay will prove to be a valuable
resource for investigations in which autophagy is considered important and is believed to be modulated.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Autophagy which literally means self-eating (auto – self; phagy
– eating) is a group of cellular processes that deliver cytoplasmic
cargoes to lysosomes for subsequent degradation. Three forms of
autophagy have been described – macroautophagy, microauto-
phagy and chaperone-mediated autophagy – which are individu-
ally characterized by the mechanism through which lysosomal
delivery occurs [1]. Macroautophagy is the most extensively stud-
ied of these processes and for simplicity we will refer to it hereafter
as autophagy.
Autophagy is initiated upon the formation of a structure called
the isolation membrane which has been shown to originate from
multiple locations within the cell [2–5]. Two ubiquitin-like mech-
anisms are then engaged to grow the membrane into a double-
membraned ball termed an autophagosome, which is the charac-
teristic organelle of this specific process. Upon autophagosomeformation, two specific events must occur that are critical for cargo
recruitment [6]. Firstly, as the membrane grows, it must incorpo-
rate a lipidated form of microtubule-associated protein light chain
3 (LC3). In cells with basal autophagy, the majority of LC3 exists as
an un-lipidated soluble form termed LC3-I in the cytoplasm. Upon
promotion of autophagy a greater proportion of LC3 becomes
conjugated to phosphatidylethanolamine to form a version of the
protein called LC3-II which integrates into the autophagosome
membrane via the lipid moiety [7]. LC3-II serves both as a
structural component of the autophagosome membrane as well
as a critical factor involved in accrual of cargo.
The second important factor for cargo recruitment is the
engagement of adaptor proteins. This group of proteins which
includes p62/SQSTM1, NBR1, OPTN and BNIP3L (Nix) act as bridges
between LC3 on the autophagosome membrane and cargoes
marked for autophagic degradation [8]. The utilization of adapter
proteins enables selectivity in autophagy. Various forms of selec-
tive autophagy have been described including pexophagy – the
selective removal of peroxisomes and mitophagy – the selective
removal of mitochondria.
Following autophagosome formation and cargo recruitment,
membrane fusions can then occur between autophagosomes and
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with a lysosome resulting in the formation of a new organelle,
the autolysosome. In this organelle, the acidic hydrolases provided
by the lysosome break down the cargo of the autophagosome into
constituent parts which are then transferred into the cytoplasm
where they are either catabolized further or recycled into
biosynthetic pathways [1].
The study of autophagy has in recent years received consider-
able attention due to its involvement and/or perturbation in
various forms of human disease [1]. In addition, because the
dynamics of autophagy can be easily regulated, there is also a lot
of interest in manipulating autophagy for therapeutic gain. For
example, studies have shown that the promotion of autophagy
can facilitate clearance of the aggregated proteins associated with
neurodegenerative diseases such as Huntington’s and Parkinson’s
disease [9]. Conversely, several studies have indicated that certain
tumours can be dependent on autophagy indicating that autoph-
agy inhibitors may be useful agents for cancer chemotherapy
[10–12].
In order to understand and have the ability to manipulate
autophagy in any given context, it is critical to be able to determine
the rate of autophagic flux in normal versus diseased cells and
before and after drug treatments. To date, the majority of studies
on autophagy utilize Western blotting to measure LC3-II levels or
immunofluorescence (IF) to detect the balance of LC3-I (diffuse
staining) versus LC3-II (punctate staining indicative of autophago-
somes). While this gives a measure of the number of autophago-
somes within either individual cells (IF) or a cell population
(Western blotting), making assessments regarding autophagic flux
by these means is problematic. This is due to the fact that auto-
phagosomes represent a transient mid-point in the entire autoph-
agy process. As a result, increased numbers of LC3-positive puncta
and/or increased LC3-II levels can represent an increase in auto-
phagosome formation, but this can conversely also represent a
blockage or impairment in autophagosome turnover following
autophagosome formation [13]. Because of this limitation, a num-
ber of other assays have been developed to monitor flux between
autophagosomes and lysosomes by monitoring for example, the
traffic of fluorescent-tagged versions of LC3 which give differentFig. 1. Parkin overexpression promotes mitophagy upon mitochondrial depolarization
mitochondria. After overexpression of exogenous YFP-Parkin and treatment with antim
mitochondria en masse.fluorescent signals at neutral pH (i.e., while in the autophagosome)
versus the more acidic pH in the lysosome [14]. These assays yield
a considerable amount of information when compared to analysis
of steady-state levels of LC3. However, they are still limited in that
they do not measure cargo digestion which is the ultimate
endpoint of the autophagy process.
The ability to monitor cargo degradation during autophagy has
been hampered by the current paucity of known specific cargos. As
a surrogate, analysis of the degradation of adapter proteins such as
p62/SQSTM1 is useful in some situations, but not in others, for
instance in cases where p62/SQSTM1 is not utilized as an adaptor
protein. In addition, the levels of p62/SQSTM1 have been shown to
be modulated at the transcriptional level in response to changes in
p62/SQSTM1 protein levels [15–17] – an event which clearly con-
founds to the ability to monitor loss of p62/SQSTM1 degradation
by autophagy. Bearing in mind the issues regarding many current
autophagy assays, we describe here the development of an assay
to monitor the autophagic degradation of mitochondria which
can be used to determine differences in the rate of autophagic
cargo digestion between different cells or in response to external
stimuli.
2. Materials and methods
2.1. Cell culture and treatments
All cell lines were cultured in DMEM (Gibco) containing 10%
FBS, 4.5 g l1 glucose, 1 mM L-glutamine, 0.11 g l1 pyruvate and
maintained at 37 C in 5% CO2 atmosphere. For mitochondria
depletion, cells were treated with 1 lM antimycin A (Sigma
A8674) and 1 lM oligomycin (Sigma O4876) every 12 h for the
indicated time periods as previously described [18]. We recom-
mend that a titration of these drugs is undertaken in different cell
systems in order to determine the most effective concentration to
cause mitochondrial damage and depletion in any given system.
In order to activate autophagy, cells were treated with 100 nM
rapamycin (LCL laboratories R-5000) or 150 lM of deferoxamine
mesylate (DFO) for 2 h prior treatment with oligomycin and
antimycin A. For the inhibition of the autophagic flux cells were. In normal conditions the ser/thr kinase PINK1 is constitutively localized at the
ycin A and oligomycin, mitochondrial proteins are depleted due to elimination of
Fig. 2. Expression of exogenous Parkin enables mitophagy. 3T3-SA cells with or
without expression of YFP-Parkin were treated with 1 lM antimycin A + 1 lM
oligomycin and analyzed by Western Blotting after 48 h using the MitoProfile
Membrane integrity WB Antibody Cocktail. Actin was used as a loading control. The
immunoblots shown are representative of what was seen in at least three
independent experiments.
Fig. 3. Induced-mitophagy can be used to measure differential autophagy kinetics in diff
were treated with 1 lM antimycin A + 1 lM oligomycin for the indicated time periods. C
WB Antibody Cocktail, and an anti-LC3B antibody. Actin was used as a loading control.
ImageJ software using the intensity of the band and expressed as mitochondria protein to
2 YFP-Parkin (⁄p < 0.05; ⁄⁄p < 0.001) and $ indicates significant difference between SVEC
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mycin A1 (Sigma) together with antimycin A and oligomycin.
2.2. Retroviral infections
3T3-SA-YFP-Parkin and SVEC-YFP-Parkin were generated as
previously described [19]. To generate Saos2-YFP-Parkin, Saos2
EcoR were retrovirally infected as previously described [20].
Briefly, Phoenix Eco packaging cells were transfected with pLZRS-
YFP-Parkin by CaPO4 precipitation. Retroviral supernatants were
added to Saos2-EcoR cells together with Polybrene (hexadimeth-
rine bromide; Sigma). After the third round of infection cells were
selected for 7 days in Zeocin (200 lg/ml, Invitrogen). To generate
ATG7 knockout mouse embryonic fibroblasts (MEFs), immortalised
ATG7flox/flox MEFs were retrovirally infected with pBabe-puro-Cre
or a retroviral vector as control. Cells were then selected in
2.5 lg/ml puromycin for 5 days. ATG7flox/flox and ATG7/ were
then retrovirally infected using pLZRS-YFP-Parkin as described
above.
2.3. Western blotting
Following treatments, all floating cells were discarded and
attached cells were lysed in buffer containing 1% triton-X, 0.1%
SDS, 50 mM HEPES pH 7.5, 150 mM NaCl, 100 mM NaF, 10 mM
EDTA, 10 mM Na4P2O7 and protease inhibitors (Roche). After
protein concentration determination using BCA assay (Sigma), cellerent cell lines. (A) 3T3-SA-YFP-Parkin, Saos2 YFP-Parkin and SVEC YFP-Parkin cells
ell lysates were analyzed by Western blot using the MitoProfile Membrane integrity
(B) Protein quantification from three independent experiments was determined by
actin ratio (%). ⁄,⁄⁄Indicate significant differences between 3T3-YFP-Parkin and Saos-
YFP-Parkin and Saos-2 YFP-Parkin. $p < 0.05; $$p < 0.01.
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lon-P membranes (Millipore). Membranes were probed with
MitoProfileMembrane Integrity WB Antibody cocktail (Abcam
ab110414), anti-LC3B (Cell Signaling Technology 2775) and anti
b-actin (Abcam ab8227) antibodies.
2.4. Statistical analysis
For time course studies, data were analyzed using a general lin-
ear model repeated ANOVA.
3. Theory
Parkin-dependent mitophagy involves PTEN-induced putative
kinase 1 (PINK1) and a ubiquitin ligase complex containing Parkin
(Fig. 1). Studies have shown that the ectopic expression of Parkin in
cells followed by treatment with agents that perturb mitochondrial
function results in the complete removal of mitochondria over
time [21,19]. We reasoned that by providing the cell with an excess
endogenous cargo (damaged mitochondria), then the rate of loss ofFig. 4. Promotion and inhibition of autophagy can be detected in cells expressing exogeno
A + 1 lM oligomycin with or without addition of 100 nM rapamycin as indicated to prom
Western blotting. The immunoblots shown are representative of what was observed in th
deferoxamine mesylate (DFO) for 1 h before adding 1 lM antimycin A + 1 lM oligomycin
the results observed on two separate occassions. (C and D) 3T3-SA YFP-Parkin cells wer
100 nM bafilomycin (D) to inhibit autophagy. After 48 h, cell lysates were analyzed for
control. The immunoblots shown are representative of what was seen in three indepenmitochondria would be directly related to the autophagic rate/flux
within the cell. As a result, we considered that that this process of
‘enhanced-mitophagy’ could be used as an assay to measure differ-
ences in autophagic flux between cells and in response to external
stimuli.
4. Results
4.1. Expression of exogenous Parkin enables ‘enhanced-mitophagy’
To test our hypothesis that enhanced-mitophagy could be uti-
lized to measure autophagic flux, we employed a commercial panel
of antibodies which enables Western blotting for a number of
mitochondrial proteins at the same time. 3T3-SA cells which had
been infected with retrovirus expressing Parkin fused to the yellow
fluorescent protein (YFP-Parkin) and parental control cells were
treated with antimycin A (an inhibitor of the electron transport
chain) and oligomycin (an inhibitor of ATP synthase) for 2 days.
Cell lysates were then prepared and examined byWestern blotting.
This revealed that over this time frame there was no noticeableus Parkin. (A) 3T3-SA cells expressing YFP-Parkin were treated with 1 lM antimycin
ote autophagy. After 16 h cells were analyzed for mitochondrial protein depletion by
ree independent experiments. (B) Saos2-YFP Parkin cells were treated with 150 lM
for 24 h. Lysates were then analyzed by Western blotting and are representative of
e treated with 1 lM antimycin A + 1 lM oligomycin /+ 10 lM chloroquine (C) or
mitochondrial protein depletion by Western blotting. Actin was used as a loading
dent experiments.
Fig. 5. Enhanced-mitophagy can detect genetic loss of autophagy. ATG7flox/flox MEFs
expressing YFP-Parkin together with either a retrovirus expressing Cre recombinase
or control virus were treated with 1 lM antimycin A + 1 lM oligomycin for 24 h.
Lysates were analyzed by Western blotting was undertaken using the MitoProfile
Membrane integrity WB Antibody Cocktail, an anti-LC3B antibody and an anti-actin
antibody as a loading control. The immunoblots shown are representative of what
was seen in three independent experiments.
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mitochondrial proteins were dramatically depleted in cells
expressing exogenous YFP-Parkin (Fig. 2).
4.2. Enhanced-mitophagy can be used to reveal differences in
autophagic flux between cells
Since autophagy is the only cellular mechanism for mitochon-
drial removal, we were interested to know if enhanced-mitophagy
could be used to reveal differences in autophagic flux between
cells. Saos-2 osteosarcoma cells and SVEC endothelial cells were
therefore infected with YFP-Parkin to enable mass elimination of
mitochondria by autophagy and the depletion of mitochondrial
proteins was measured in these and YFP-Parkin-expressing 3T3-
SA cells following treatment with antimycin A and oligomycin. This
revealed that not only were there significant differences in the rate
of loss of mitochondrial proteins between different cell lines, but
there were also differences in the rate of depletion of different
mitochondrial proteins in each individual cell line Fig. 3A and B).
Notably, cytochrome c and Porin (also known as VDAC1) are
depleted very rapidly in SVEC and 3T3-SA after treatment with
antimycin A and oligomycin (Fig. 3A and B). As a result, we did
not consider them useful in determining differential rates of
autophagy in these cells over this time frame.
By contrast to the rapid loss of cytochrome c and Porin, deple-
tion of Complex Va (CVa), Complex III Core 1 (Core 1) and cyclophi-
lin D occurred at a progressive rate following treatment with
antimycin A and oligomycin that was differential between the
three cell lines analyzed (Fig. 3A). Quantification of the rate of loss
of Core 1 and cyclophilin D revealed that depletion was signifi-
cantly more rapid in 3T3-SA and SVEC when compared to Saos-2
(Fig. 3B). This indicates a quicker loss of mitochondria in 3T3-SA
and SVEC which we consider is due to differences in the autophagic
rate between these cells and Saos-2. To address this point further,
we also analyzed the relative accumulation of the classical autoph-
agy markers LC3-II and p62 in the three cell lines following treat-
ment with the autophagy inhibitor, chloroquine. This revealed that
the accumulation of LC3-II and p62 was much slower in Saos-2
cells when compared with 3T3-SA and SVEC indicating that Saos-
2 have a lower autophagic rate (Supplementary Fig. 1A and B).
Since this result is completely in line with what we observed using
enhanced-mitophagy, we conclude that by providing a large pool
of endogenous substrate our assay measures differences in the
general autophagic flux/capacity of the cell and does not simply
reveal differences in mitophagy.
4.3. Enhanced-mitophagy can detect changes in autophagic flux
caused by external stimuli or genetic loss of an essential autophagy
gene
To determine if loss of CVa, Core 1 and cyclophilin D following
treatment with antimycin A and oligomycin was occurring by
autophagy, we sought to determine if the loss of these proteins
could be affected by agents that are known to affect autophagic
flux. To this end, we firstly treated cells with rapamycin which is
a well characterized inhibitor of mTOR Complex 1 and a potent
inducer of autophagy (Supplementary Fig. 2A and B) [22] and with
deferoxamine mesylate (DFO), a hypoxia mimetic and previously
described inducer of autophagy [23]. Treatment with these drugs
alone had little impact on the levels of mitochondrial proteins.
However, in cells treated with rapamycin or DFO together with
antimycin A and oligomycin there was a marked depletion of mito-
chondrial proteins that was greater than that observed in cells
treated with antimycin A and oligomycin alone (Fig. 4A and B).
The difference in loss of CVa, Core 1 and cyclophilin D caused by
treatment was particularly clear, underscoring the usability ofthese proteins as markers of autophagic flux in these cells. A small
difference was also seen for Porin in response to rapamycin, how-
ever, no change in cytochrome c levels was evident with either
drug, ruling out its applicability in this assay.
We next assessed if the loss of mitochondrial proteins following
treatment with antimycin A and oligomycin was affected by inhi-
bition of autophagy. To do this we treated cells with the lysosomo-
tropic agents hydroxychloroquine (Cq) or bafilomycin A1 (Baf A1)
which raise the pH of the lysosome, thereby restricting the turn-
over stage of autophagy. As evidence of the effectiveness of these
treatments, an accumulation of LC3-II was observed upon treat-
ment with either drug (Fig. 4C and D). Treatment with Cq or Baf
A1 also raised the levels of cytochrome c and reduced the levels
of Porin (Fig. 4C and D). By contrast, the levels of CVa, Core 1 and
cyclophilin D were largely unaffected (Fig. 4C and D).
The effect of Cq and Baf A1 on the loss of mitochondrial proteins
upon exposure to antimycin A and oligomycin was also assessed.
This revealed that the loss of CVa, Core 1 and cyclophilin D caused
by antimycin A and oligomycin could be reversed by treatment
with Cq and Baf A1 (Fig. 4C, D and Supplementary Fig. 3A, B). A sta-
tistically significant restoration of CVa, Core 1 and cyclophilin D lev-
els was observed in response Cq (Fig. 4C and Supplementary Fig. 3A)
and a statistically significant restoration of CVa and Core 1 was
achieved by treatment with Baf A1 (Fig. 4D and Supplementary
Fig. 3B). These data therefore confirm that CVa, Core 1 and cyclophi-
lin D are indeed lost by autophagy upon treatment with antimycin
A and oligomycin and that they can be used as reliable readouts of
autophaghic flux in this method of enhanced-mitophagy.
We lastly decided to test if enhanced-mitophagy can detect
genetic loss of autophagy. To do this we isolated fibroblasts from
E13.5 mouse embryos which were homozygous for a floxed allele
of the essential autophagy gene Atg7. Following isolation and
immortalization, this floxed allele was recombined in vitro by
infection with a retrovirus expressing Cre recombinase, with an
110 A.D. Baudot et al. /Methods 75 (2015) 105–111‘empty’ retroviral vector being used as control (Fig. 5). Subsequent
infection of these cells with YFP-Parkin resulted in virtually com-
plete ablation of CVA, Core 1, Porin, cyclophilin D and cytochrome
cwhen control cells were treated with antimycin A and oligomycin
(Fig. 5). By contrast, in YFP-Parkin-expressing Atg7-null cells while
loss of Porin and cytochrome c occurs in a similar manner to what
was observed in control cells, the depletion of CVa, Core 1 and
cyclophilin D was markedly impaired due to loss of autophagy
(Fig. 5). We therefore conclude that enhanced-mitophagy can be
used to detect genetic loss of autophagy and that CVa, Core 1
and cyclophilin D are once again the reliable mitochondrial
proteins to monitor when using this assay.5. Concluding remarks
We describe here a method to analyze autophagic flux based on
a system we have termed ‘enhanced-mitophagy’. We show that
using this system we can detect differences in autophagic flux
between different cell lines, in response to external stimuli and
upon genetic loss of an essential autophagy gene. We believe this
assay to be a true measure of the autophagic capacity of cells to
degrade an endogenous cargo. As such, we consider it is much
more informative than many current assays to measure autophagy.
In this regard, it is notable that the changes we observed in the
autophagic degradation of mitochondrial proteins is in line with
what could be inferred regarding flux rates from LC3 and p62
Westerns in these cells. However, the analysis of LC3 by Western
blotting alone cannot be extrapolated to make definitive state-
ments regarding cargo digestion and p62 analysis is known to be
hampered in some systems by changes in the expression as well
as the degradation of the protein [15–17]. As a result, since analysis
of LC3 and p62 has limitations, we believe that the enhanced-mito-
phagy assay has great value in complementing analysis of these
proteins as markers of successful autophagy. It should be noted,
however, that while we consider that enhanced-mitophagy can
be used to assay the general autophagic flux/capacity of the cell
and not just mitophagy, it cannot be used as a measure of the deg-
radation rate of all potential autophagic cargoes. While it can be
assumed that all cargoes are affected by the general autophagic
flux/capacity of the cell, their degradation will for example, also
be dependent on specific cues, protein modifications and the avail-
ability of sufficient amounts of any required adaptor proteins.
Perhaps one surprising outcome from this study was the reali-
zation that the depletion of different mitochondrial proteins was
not equivalent upon treatment with antimycin A and oligomycin.
We found that CVa, Core 1 and cyclophilin D were progressively
depleted in a way that could reveal differences in autophagic rate
between cells and that the levels of these proteins behaved as
expected when autophagy was either promoted or inhibited. We
therefore consider these proteins to be reliable readouts of auto-
phagic flux when using this enhanced-mitophagy assay in these
cells. By contrast, the levels of Porin and cytochrome c underwent
changes following treatment with antimycin A and oligomycin that
cannot be explained solely by changes in autophagic flux. For
example, Porin levels decreased upon treatment with Cq and cyto-
chrome c levels increased in this context without an equivalent
increase in other mitochondrial proteins such as CVa and Core 1.
It is easy to rationalize that cytochrome c may be affected in a
manner independent of the absolute levels of mitochondria since
for example, it is well established that cytochrome c can be
released from mitochondria in response to certain apoptotic stim-
uli [24]. Changes in Porin levels, are though less easy to explain
since it is an integral membrane protein in the outer mitochondrial
membrane. It has, however, previously been shown that Tom20 –
another mitochondrial outer membrane protein – is ubiquitylatedby Parkin and turned over in the proteasome [25]. Since Porin is
also directly ubiquitylated by Parkin it may also be possible that
it is targeted for degradation in a manner independent of mito-
phagy [26]. This is undoubtedly worthy of further investigation
in future studies. For the purposes of this study, however, from
what we have observed we do not consider Porin and cytochrome
c to be reliable markers of autophagic flux in the cells analyzed. As
a result, we would advocate caution in the analysis of these pro-
teins when using this enhanced-mitophagy assay in other systems.
We would also like to make clear why we used antimycin A and
oligomycin in our study and not the more conventional mitochon-
drial uncoupler carbonyl cyanide m-chlorophenylhydrazone
(CCCP). This decision was made in light of previous studies which
have shown that CCCP can interfere with the degradation of auto-
phagic cargoes in the lysosome [27]. As a result, we do not recom-
mend using CCCP in the enhanced-mitophagy assay.
Finally, while we conclude from this study that enhanced-mito-
phagy is a reliable assay of autophagic flux in 3T3-SA, Saos-2 and
SVEC cells, we would also argue that this assay would be broadly
applicable in multiple situations. Using the retroviral construct
that we describe here, we believe that the assay could be utilized
in multiple cell culture systems. In addition, the production of a
YFP-Parkin lentivirus should also permit application of this assay
in non-dividing cells, for example in senescent cell cultures or in
the analysis of non-dividing tissue ex vivo. Moreover, through the
utilization of different fluorescent tags (YFP or otherwise), it may
also be possible to measure changes in autophagic flux in vivo,
for example following drug treatment of animals carrying tumor
xenografts which have been engineered to express a fluorescent-
tagged Parkin and a fluorescent-tagged mitochondrial protein such
CVa or cyclophilin D. We hope therefore that the findings we
describe in this study act as a starting point for future studies
designed to analyze autophagic flux in multiple experimental sys-
tems and in a variety of situations in which autophagy is consid-
ered important.Acknowledgements
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